UTSouthwestern Medical Center has received a significant grant from the Advanced Research Projects Agency for Health (ARPA-H) to develop a groundbreaking solution for organ transplantation. The project, known as Vascularized Immunocompetent Tissue as an Alternative Liver (VITAL), aims to create functioning artificial livers using patients' own cells and 3D printing technology. If successful, this approach could revolutionize liver transplantation, offering a potential cure for liver cirrhosis and chronic liver diseases, which claim approximately 50,000 lives annually in the U.S. alone.
The VITAL project is led by Dr. Muhammad Rizwan, an Assistant Professor of Biomedical Engineering and Ophthalmology at UTSouthwestern. Dr. Rizwan and his team will harvest cells from patients with liver disease, convert them into induced pluripotent stem cells (iPSCs), and then use these cells to create liver tissue. This tissue will be combined with a hydrogel 'bioink' for 3D printing, resulting in fully functional artificial livers. The team aims to test these bioprinted livers in animal models and potentially in humans within five years.
One of the key advantages of this approach is that the artificial livers will be personalized, made from the patient's own cells, eliminating the need for lifelong immunosuppression, a common challenge in traditional liver transplants. Additionally, the process of developing these livers from scratch is expected to provide valuable insights into natural liver function, aiding in the understanding and treatment of liver diseases. The artificial livers will also be instrumental in evaluating the safety and efficacy of new pharmaceuticals.
UTSouthwestern's expertise in solid organ transplantation, coupled with its robust research facilities and collaborative environment, positions it as an ideal location for this project. The institution's commitment to translating scientific discoveries into real-world solutions makes it a leader in the field of biomedical innovation. The project is supported by ARPA-H, with a grant of up to $25 million, and involves a multidisciplinary team of engineers, clinicians, and scientists working together to make functional organ printing a reality.
